GlaxoSmithKline, which is cutting back mostly neither in detailing nor in sampling, failed to disclose safety data about Avandia, Wellbutrin, and Paxil, thus allegedly violating the False Claims Act, which they settled with $3 billion.
GlaxoSmithKline, which is cutting back mostly neither in detailing nor in sampling, failed to disclose safety data about Avandia, Wellbutrin, and Paxil, thus allegedly violating the False Claims Act, which they settled with $3 billion.